Dizal (Jiangsu) Pharmaceutical (SHA:688192) will present a poster on its sunvozertinib drug at the World Conference on Lung Cancer in Seoul from Sept. 12 to 15, according to a Saturday filing with the Shanghai bourse.
Sunvozertinib received China and U.S. approval for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations with resistance to platinum-based chemotherapy, the filing said.